ENDRA Life Sciences Achieves Intellectual Property Milestone with Issuance of Three New Patents
08 Novembro 2023 - 10:00AM
Business Wire
Global intellectual property portfolio
increases to 70 issued patents
ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of
Thermo Acoustic Enhanced UltraSound (TAEUS®), announces the
issuance of three new patents, including one in the U.S. and two in
China. ENDRA’s intellectual property (IP) portfolio now includes 70
issued patents worldwide, enhancing the IP protection for the novel
TAEUS® system.
The following three patents were issued:
- U.S. Patent No. 11806113, titled “Thermoacoustic Probe,”
relates to a novel thermoacoustic probe with an optical transducer
and an integrated wedge. This builds upon ENDRA’s U.S. Patent No.
11730374, which defines and protects ENDRA’s integrated wedge
technology.
- Chinese Patent No. ZL 2021800299011 (the ‘011 patent), titled
“Thermoacoustic Transducer with Integrated Switch,” relates to a
novel system for reducing false signals in thermoacoustic imaging.
ENDRA expects the ‘011 patent to be effective for all
thermoacoustic imaging applications. The Chinese ‘011 patent is
related to its parent patent, U.S. Patent No. 11172829.
- Chinese Patent No. ZL 2022800094336 (the ‘336 patent), titled
“Acoustically Isolated Thermoacoustic Imaging Probe and Process of
Manufacture,” protects ENDRA’s proprietary manufacturing process to
acoustically isolate the radiofrequency element from the transducer
element. The Chinese ‘336 patent is related to its parent patent,
U.S. Patent No. US10996163.
"Our IP portfolio has reached a new milestone of 70 issued
patents globally. We believe this is a remarkable achievement for a
company of our size and a testament to the innovation of ENDRA,"
stated ENDRA's Chairman and Chief Executive Officer Francois
Michelon. “These newly issued patents protect and further
differentiate ENDRA's thermoacoustic systems in areas of high unmet
clinical need, such as the early detection of steatotic liver
disease."
About ENDRA Life Sciences Inc.
ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced
UltraSound (TAEUS®), a ground-breaking technology being developed
to visualize tissue like MRI, but at 1/50th the cost and at the
point of patient care. TAEUS® is designed to work in concert with
over 700,000 ultrasound systems in use globally today. TAEUS® is
initially focused on the measurement of fat in the liver as a means
to assess and monitor Steatotic Liver Disease (SLD) (formerly known
as NAFLD-NASH), a chronic liver spectrum that affects over two
billion people globally, and for which there are no practical
diagnostic tools. Beyond the liver, ENDRA is exploring several
other clinical applications of TAEUS®, including visualization of
tissue temperature during energy-based surgical procedures. For
more information, please visit www.endrainc.com.
Forward-Looking Statements
All statements in this press release that are not based on
historical fact are “forward-looking statements” within the meaning
of Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934. Forward-looking statements, which
are based on certain assumptions and describe our future plans,
strategies and expectations, can generally be identified by the use
of terms such as “approximate,” “anticipate,” “attempt,” “believe,”
“could,” “estimate,” “expect,” “forecast,” “future,” “goal,”
“hope,” “intend,” “may,” “plan,” “possible,” “potential,”
“project,” “seek,” “should,” “will,” “would,” or other comparable
terms (including the negative of any of the foregoing), although
some forward-looking statements are expressed differently. Examples
of forward-looking statements for ENDRA include, among others:
estimates of the timing of future events and anticipated results of
our development efforts, including the timing of submission for and
receipt of required regulatory approvals and product launches;
statements relating to future financial position and projected
costs and revenue; expectations concerning ENDRA’s business
strategy; and statements regarding ENDRA’s ability to find and
maintain development partners. Forward-looking statements involve
inherent risks and uncertainties that could cause actual results to
differ materially from those in the forward-looking statements as a
result of various factors including, among others: the ability to
raise additional capital in order to continue as a going concern;
the ability to obtain regulatory approvals necessary to sell ENDRA
medical devices in certain markets in a timely manner, or at all;
the ability to develop a commercially feasible technology and its
dependence on third parties to design and manufacture its products;
the impact of COVID-19 on ENDRA’s business plans; the ability to
find and maintain development partners; market acceptance of
ENDRA’s technology and the amount and nature of competition in its
industry; ENDRA’s ability to protect its intellectual property; and
the other risks and uncertainties described in the Risk Factors and
Management’s Discussion and Analysis of Financial Condition and
Results of Operations sections of the Company’s most recent Annual
Report on Form 10-K and in subsequent Quarterly Reports on Form
10-Q filed with the SEC. You should not rely upon forward-looking
statements as predictions of future events. The forward-looking
statements made in this press release speak only as of the date of
issuance, and ENDRA assumes no obligation to update any such
forward-looking statements to reflect actual results or changes in
expectations, except as otherwise required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231108641564/en/
Company Contact: Irina Pestrikova Senior Director,
Finance investors@endrainc.com www.endrainc.com
Investor Relations Contact: Yvonne Briggs LHA Investor
Relations (310) 691-7100 ybriggs@lhai.com
ENDRA Life Sciences (NASDAQ:NDRA)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
ENDRA Life Sciences (NASDAQ:NDRA)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024